List of Biotech, Pharmaceutical & Life Sciences companies in South Carolina - 15

We are Afaxys, a first-of-its-kind, socially conscious healthcare company whose name is derived from a combination of affordable and access. Our mission is to provide affordable access for all who need it. This simple but powerful mission shapes the work we do every day Our promise is to be Mission Driven. Customer Focused.® With community/public health providers as our partners, we ensure dependable and affordable contraceptive care is available to everyone – because access to reproductive healthcare should be a right, not a privilege, for ALL patients.

ARCpoint Labs is a trusted industry leader serving our communities with drug, alcohol, DNA, and clinical testing solutions. With more than 100 independently owned locations, we are committed to providing accurate, cost-effective solutions for consumers, businesses, and physicians nationwide. As one of the fastest growing third-party administrators for testing solutions, ARCpoint Labs continues to innovate and expand its offerings to better meet the needs of our communities. ARCpoint Labs offers businesses a reliable partner for all drug and alcohol testing, policy development, and supervisory training in addition to convenient SARS-CoV-2 testing solutions. Our offerings are built by our dedication to providing safe and drug/alcohol-free workplaces. Many ARCpoint Labs locations offer affordable walk-in wellness solutions and clinical lab screenings to help individuals take control of their overall health and well-being.

CeQur®, a medical device company dedicated to simplifying mealtime insulin delivery for individuals on multiple daily injections, manufactures CeQur Simplicity, a simple-to-use wearable insulin delivery device enabling discreet, convenient and injection-free bolus dosing. In June 2024, the company announced the FDA's recent 510(k) clearance of CeQur Simplicity for an extended wear duration from 3 to 4 days. One CeQur Simplicity 4-day wearable patch holds up to 200 units of rapid-acting insulin administered in two-unit increments and replaces, on average, twelve daily mealtime injections over four days. CeQur is headquartered in Horw, Switzerland. Please visit myceqursimplicity.com for more information.

CharlestonPharma is a biopharmaceutical company that develops a lead IgG1 monoclonal antibody targeting nucleolin transporter on tumor cells to induce apoptosis and cell death in various cancer cell lines.

Clemson University is a higher education institution that offers health, wellness, and fitness services.

Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada. Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need. The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize On 8/6/24 Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.

Doty Scientific, Inc. was founded by Dr. F. David Doty (president and chief engineering scientist) in May 1982, in Columbia, South Carolina, for the primary purpose of designing and manufacturing scientific instrumentation. The company’s initial product was a CP/MAS (Cross Polarization/Magic Angle Spinning) probe for chemical structure determination of solid materials via Nuclear Magnetic Reso­nance (NMR).

Elastrin Therapeutics is a South Carolina-based biotech developing novel therapies to reverse cardiovascular disease. Its underlying technology was developed by Dr. Naren Vyavahare during the last 20 years at Clemson University, in collaboration with Dr. Charles Rice. Our team built a proprietary platform that targets and restores degraded elastin by removing the harmful calcification that stiffens arteries. The platform significantly improves the efficacy of drugs and eliminates side effects by combining particle design with elastin targeting.

High-Purity Standards is a provider of high quality spectrometric standards and reference materials for various analytical techniques, including AAS, ICP, GC, GC-MS, IC, and ISO Guide 34 multi-component organic reference.

Kiyatec is disrupting cancer care by accurately predicting patient–specific response and non–response before treatment begins. We utilize the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies in our CLIA-certified and research laboratories. Our goal is to enable physicians to isolate only the effective treatments for their patients as quickly as possible - making true personalized medicine a reality. Our approach has been validated through engagements with leading cancer hospitals, multiple top 10 pharmaceutical companies and the NCI. We are conducting robust clinical trials to fully demonstrate the power of our approach and earn widespread adoption for a broad portfolio of products predicting response to today’s and tomorrow’s therapies. www.kiyatec.com

Nephron Pharmaceuticals Corporation is a leading manufacturer of inhalation products, medical-grade nitrile gloves, and sterile pre-filled medications. The company began in 1997 and has continued to set the standard for sterile pharmaceutical manufacturing since. Nephron Pharmaceuticals' mission is to achieve better healthcare outcomes.

Phi Life Sciences is a Molecular Diagnostic and Laboratory Service company that aims to help patients by reducing disease mortality and adverse drug reactions through affordable, state of the art screening and diagnostic technologies. Phi Life Sciences is the bridge between scientists with innovative technologies and the patients and doctors whom they can benefit. We build this bridge through products developed in laboratory services and offered to patients and doctors through clinical services. Phi Life sciences aims to improve the efficiency, delivery, accessibility, and utility of molecular testing services through innovative technologies, licensed products, and clinically actionable result that empower physicians to deliver precision treatments and diagnoses by incorporating molecular tests that will improve their patients' health. Phi Life Sciences aims to improve patient health through the use of cutting edge molecular diagnostic tools. We exist to achieve the human potential.

The Ritedose Corporation is a leader in blow-fill-seal(BFS) manufacturing of small fill volume pharmaceutical unit dose sterile and non-sterile liquids. We specialize in manufacturing inhalation products, eye drops, eardrops and unit dose oral liquids.

Spectral Medical is a Phase 3 company advancing the fight against endotoxic septic shock through an innovative theranostic approach. This unique strategy combines the EAA™ Endotoxin Activity Assay, the only FDA-cleared diagnostic for the risk of developing sepsis, with targeted rapid therapy using Toraymyxin™ (PMX). PMX is a Polymyxin B extracorporeal direct hemoadsorption column which is highly effective in removing endotoxin in the bloodstream. Already approved in Japan and Europe (1994 and 2002 respectively), PMX has been safely used on over 340,000 patients. Spectral holds exclusive U.S. development and commercialization rights for PMX since 2009, with a distribution agreement for Canada since 2010. In July 2022, the FDA granted Breakthrough Device Designation to PMX for treating endotoxic septic shock, a condition that affects around 330,000 people in North America annually. Spectral is currently conducting the Tigris Trial, a confirmatory study evaluating PMX combined with standard care vs. standard care alone in a 2:1 randomized trial of 150 patients, utilizing Bayesian statistics to assess its effectiveness. The trial methods are detailed in the Critical Care publication “Bayesian methods: a potential path forward for sepsis trials." https://doi.org/10.1186/s13054-023-04717-x

Zylö develops Z-pods® that are highly engineered amorphous silica particles designed to encapsulate compounds and improve product performance in a wide range of market segments.